Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Kelonia: redirecting in vivo gene therapy

Kelonia has a team of bluebird veterans and a $50 million series A round to tackle gene therapy’s delivery problem

April 28, 2022 10:37 PM UTC

Kelonia is taking on one of the biggest challenges in gene therapy development with a new in vivo lentivirus-based platform designed to move the modality outside the liver. 

For its first program, the company is using its gene therapy delivery platform to add CARs to T cells inside the body, making it the latest company to join the small but growing in vivo CAR T cell field...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article